PPAR-Beta / Delta Agonist Pipeline Insights, 2019 Report Featuring Genfit, CymaBay Therapeutics, Inventiva Pharma, Chipscreen Biosciences, & Senju Pharmaceutical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “PPAR-Beta
/ Delta Agonist -Pipeline Insight, 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.

PPAR-Beta / Delta Agonist – Pipeline Insight, 2019 report offers
comprehensive insights of the pipeline (under development) therapeutics
scenario and growth prospects across PPAR-Beta / Delta Agonist
development. The report provides detailed coverage of the pipeline
landscape for this mechanism of action, equipped with data from multiple
sources with complete pipeline analysis by developmental stage,
associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for PPAR-Beta /
Delta Agonist – Pipeline therapeutics development coverage provides
descriptive product profiles including (but not limited to) drug
description, product development and R&D activities encompassing
clinical and pre-clinical studies, designations, collaborations,
licensing deals, grants, technologies and patent details.

The report assesses the active PPAR-Beta / Delta Agonist pipeline
products by developmental stage, product type, molecule type, and
administration route.

Scope of the report

• Provides a snapshot of the therapeutics pipeline activity for
  PPAR-Beta / Delta Agonist
• Features the PPAR-Beta / Delta Agonist pipeline across the complete
  product development cycle including all clinical and non-clinical
  stages
• Offers detailed therapeutic product profiles of PPAR-Beta / Delta
  Agonist with key coverage of developmental activities including
  licensing & collaboration deals, patent details, designations,
  technologies, indications and chemical information
• Therapeutic assessment of the active pipeline products by stage,
  product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across
  PPAR-Beta / Delta Agonist

Key Topics Covered:

1. Report Introduction

2. PPAR-Beta / Delta Agonist – Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for PPAR-Beta / Delta Agonist

4. Comparative Analysis

5. PPAR-Beta / Delta Agonist Pipeline Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. PPAR-Beta / Delta Agonist Pipeline Products in Non-clinical
Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Genfit
• CymaBay Therapeutics
• Inventiva Pharma
• Chipscreen Biosciences
• Senju Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vtjy5m

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs